Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
53 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | recruiting | Phase 2 / Phase 3 | 626 | Mirati Therapeutics Inc.INDUSTRY | 47 | Sep 16, 2026 | clinicaltrials |
| NCT01949129 | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia | recruiting | Phase 2 / Phase 3 | 1,800 | St. Anna KinderkrebsforschungOTHER | 31 | Sep 4, 2026 |
| clinicaltrials |
| NCT05888844 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | active not recruiting | Phase 2 | 63 | Incyte CorporationINDUSTRY | 15 | Aug 17, 2026 | clinicaltrials |
| NCT05853575 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | active not recruiting | Phase 2 | 200 | Mirati Therapeutics Inc.INDUSTRY | 18 | Aug 14, 2026 | clinicaltrials |
| NCT05661578 | A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors(SKYSCRAPER-11) | completed | Phase 2 | 64 | Hoffmann-La RocheINDUSTRY | 9 | Jun 18, 2026 | clinicaltrials |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC(KANGUROO) | recruiting | Phase 2 / Phase 3 | 71 | Urovant Sciences GmbHINDUSTRY | 16 | Jun 15, 2026 | clinicaltrials |
| NCT04844866 | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients(DALY 2-EU) | recruiting | Phase 2 | 213 | Miltenyi Biomedicine GmbHINDUSTRY | 14 | Jun 10, 2026 | clinicaltrials |
| NCT04381650 | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 161 | TakedaINDUSTRY | 9 | Dec 10, 2025 | clinicaltrials |
| NCT03498521 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site(CUPISCO) | completed | Phase 2 | 529 | Hoffmann-La RocheINDUSTRY | 33 | Nov 19, 2025 | clinicaltrials |
| NCT04447755 | A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)(E7080-G000-231) | completed | Phase 2 | 127 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Oct 3, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | terminated | Phase 2 | 63 | Debiopharm International SAINDUSTRY | 23 | Feb 7, 2024 | clinicaltrials |
| NCT02292979 | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.(BREACH) | completed | Phase 2 | 170 | The Lymphoma Academic Research OrganisationOTHER | 5 | Aug 19, 2022 | clinicaltrials |
| NCT02978716 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) | terminated | Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 8 | Mar 23, 2022 | clinicaltrials |
| NCT02190721 | A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement | completed | Phase 2 | 50 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 8 | Dec 10, 2021 | clinicaltrials |
| NCT00865969 | Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma(PTCL) | completed | Phase 2 | 129 | Spectrum Pharmaceuticals, IncINDUSTRY | 17 | Oct 29, 2021 | clinicaltrials |
| NCT00545129 | A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone | completed | Phase 2 | 59 | PfizerINDUSTRY | 13 | Jun 18, 2021 | clinicaltrials |
| NCT00830180 | Open Label Extension In Cancer Patients | completed | Phase 2 | 41 | PfizerINDUSTRY | 10 | Apr 5, 2021 | clinicaltrials |
| NCT03771820 | Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen | unknown | Phase 2 | 136 | NanoCarrier Co., Ltd.INDUSTRY | 8 | Mar 17, 2021 | clinicaltrials |
| NCT00722553 | Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | completed | Phase 2 | 30 | Acrotech Biopharma Inc.INDUSTRY | 6 | Dec 17, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT00924209 | A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer | terminated | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 2 | Nov 30, 2018 | clinicaltrials |
| NCT03705442 | Probiotics as Adjuvant Therapy in the Treatment of Metastatic Colorectal Cancer(Probat-tmcc-17) | unknown | Phase 2 | 76 | Marin GolčićOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT02913859 | Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer | unknown | Phase 2 | 60 | University Hospital Sestre MilosrdniceOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT00741260 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | completed | Phase 1 / Phase 2 | 105 | Puma Biotechnology, Inc.INDUSTRY | 11 | Sep 5, 2018 | clinicaltrials |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer(NEFERTT) | completed | Phase 2 | 479 | Puma Biotechnology, Inc.INDUSTRY | 35 | Aug 22, 2018 | clinicaltrials |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | completed | Phase 2 | 233 | Puma Biotechnology, Inc.INDUSTRY | 31 | Aug 9, 2018 | clinicaltrials |
| NCT01860638 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | completed | Phase 2 | 296 | Hoffmann-La RocheINDUSTRY | 15 | Apr 30, 2018 | clinicaltrials |
| NCT00976989 | A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer | completed | Phase 2 | 225 | Hoffmann-La RocheINDUSTRY | 20 | Feb 6, 2017 | clinicaltrials |
| NCT00674973 | A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 207 | Hoffmann-La RocheINDUSTRY | 19 | Jun 17, 2016 | clinicaltrials |
| NCT00479752 | Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer(CORE 2) | completed | Phase 2 | 151 | Central European Cooperative Oncology GroupOTHER | 13 | Feb 18, 2016 | clinicaltrials |
| NCT00124566 | Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | completed | Phase 2 | 135 | Eisai Inc.INDUSTRY | 9 | Jan 18, 2016 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT01263886 | Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer(DISRUPT) | completed | Phase 2 | 176 | SanofiINDUSTRY | 13 | Dec 21, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT00652366 | A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 467 | Hoffmann-La RocheINDUSTRY | 23 | Feb 11, 2015 | clinicaltrials |
| NCT00576758 | GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 175 | Hoffmann-La RocheINDUSTRY | 17 | Aug 19, 2014 | clinicaltrials |
| NCT00441168 | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma | terminated | Phase 2 | 30 | Janssen-Cilag International NVINDUSTRY | 7 | Mar 21, 2014 | clinicaltrials |
| NCT00079261 | Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 25 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00838240 | Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia(AML-14A) | unknown | Phase 1 / Phase 2 | 114 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Jul 20, 2012 | clinicaltrials |
| NCT00006122 | Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 106 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Jul 16, 2012 | clinicaltrials |
| NCT00003148 | Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | completed | Phase 2 | 86 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 2, 2012 | clinicaltrials |
| NCT00286130 | Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 150 | Central European Cooperative Oncology GroupOTHER | 13 | May 1, 2012 | clinicaltrials |
| NCT00813072 | Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 135 | PharmaEngineINDUSTRY | 6 | Mar 2, 2012 | clinicaltrials |
| NCT01196455 | Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer | unknown | Phase 2 | 39 | Croatian Cooperative Group for Clinical Research in OncologyOTHER | 1 | Sep 8, 2010 | clinicaltrials |
Data updated 13 days agoSource updated unknownsource: clinicaltrials